Fuzionaire Diagnostics is a radiopharmaceutical company on a mission to develop accessible theranostics to fight cancer. With origins in Nobel laureate Robert Grubbs' lab at Caltech, our patented HetSiFA library can create theranostic radiopharmaceutical candidates from disease-targeting peptides and other ligands within weeks. Our platform also enables unique flexibility in the choice of the radionuclide used for imaging or therapy and offers manufacturing advantages in a clinical setting that enable the wider use of these important precision treatments. For more, visit us at: www.fuzionairedx.com